FR24C1012I1 - Alpha-glucosidase acide très puissante ayant des hydrates de carbone améliorés - Google Patents
Alpha-glucosidase acide très puissante ayant des hydrates de carbone améliorésInfo
- Publication number
- FR24C1012I1 FR24C1012I1 FR24C1012C FR24C1012C FR24C1012I1 FR 24C1012 I1 FR24C1012 I1 FR 24C1012I1 FR 24C1012 C FR24C1012 C FR 24C1012C FR 24C1012 C FR24C1012 C FR 24C1012C FR 24C1012 I1 FR24C1012 I1 FR 24C1012I1
- Authority
- FR
- France
- Prior art keywords
- glucosidase
- acid alpha
- improved carbon
- carbon hydrates
- highly powerful
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 CARBON HYDRATES Chemical class 0.000 title 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 108010028144 alpha-Glucosidases Proteins 0.000 title 1
- 229910052799 carbon Inorganic materials 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462057842P | 2014-09-30 | 2014-09-30 | |
| US201462057847P | 2014-09-30 | 2014-09-30 | |
| US201562112463P | 2015-02-05 | 2015-02-05 | |
| US201562135345P | 2015-03-19 | 2015-03-19 | |
| PCT/US2015/053252 WO2016054231A1 (fr) | 2014-09-30 | 2015-09-30 | Alpha-glucosidase acide très puissante ayant des hydrates de carbone améliorés |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR24C1012I1 true FR24C1012I1 (fr) | 2024-05-24 |
Family
ID=55631441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR24C1012C Active FR24C1012I1 (fr) | 2014-09-30 | 2024-03-28 | Alpha-glucosidase acide très puissante ayant des hydrates de carbone améliorés |
Country Status (36)
| Country | Link |
|---|---|
| US (5) | US10208299B2 (fr) |
| EP (2) | EP4273241A3 (fr) |
| JP (3) | JP6851964B2 (fr) |
| KR (3) | KR102306577B1 (fr) |
| CN (2) | CN114540327A (fr) |
| AU (2) | AU2015325028B2 (fr) |
| BR (1) | BR112017005810A2 (fr) |
| CA (2) | CA3228032A1 (fr) |
| CL (1) | CL2017000722A1 (fr) |
| CO (1) | CO2017002776A2 (fr) |
| CR (1) | CR20170107A (fr) |
| DK (1) | DK3201320T3 (fr) |
| DO (1) | DOP2017000079A (fr) |
| EA (1) | EA038986B1 (fr) |
| EC (1) | ECSP17019103A (fr) |
| ES (1) | ES2967620T3 (fr) |
| FI (2) | FI3201320T3 (fr) |
| FR (1) | FR24C1012I1 (fr) |
| HR (1) | HRP20240041T1 (fr) |
| HU (2) | HUE064629T2 (fr) |
| IL (4) | IL289383B2 (fr) |
| LT (1) | LT3201320T (fr) |
| MX (2) | MX2017003989A (fr) |
| MY (1) | MY186336A (fr) |
| NI (1) | NI201700039A (fr) |
| PE (1) | PE20170906A1 (fr) |
| PH (1) | PH12017500455A1 (fr) |
| PL (1) | PL3201320T3 (fr) |
| PT (1) | PT3201320T (fr) |
| RS (1) | RS65066B1 (fr) |
| SG (2) | SG10202003753PA (fr) |
| SI (1) | SI3201320T1 (fr) |
| SV (1) | SV2017005416A (fr) |
| TN (1) | TN2017000082A1 (fr) |
| WO (1) | WO2016054231A1 (fr) |
| ZA (2) | ZA201701945B (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA038986B1 (ru) | 2014-09-30 | 2021-11-18 | Амикус Терапьютикс, Инк. | Высокоактивная кислая альфа-глюкозидаза с повышенным содержанием углеводов |
| EP3397273B1 (fr) * | 2015-12-30 | 2021-05-19 | Amicus Therapeutics, Inc. | Alpha-glucosidase acide améliorée pour le traitement de la maladie de pompe |
| EA201891507A1 (ru) * | 2015-12-30 | 2018-12-28 | Амикус Терапьютикс, Инк. | Кислая альфа-глюкозидаза усиленного действия для лечения болезни помпе |
| WO2017173060A1 (fr) | 2016-03-30 | 2017-10-05 | Amicus Therapeutics, Inc. | Formulations comprenant une alpha-glucosidase acide recombinante |
| TWI823272B (zh) * | 2016-03-30 | 2023-11-21 | 美商阿米庫斯醫療股份有限公司 | 用於選擇高m6p重組蛋白之方法 |
| IL295551A (en) * | 2016-03-30 | 2022-10-01 | Amicus Therapeutics Inc | A method for selecting recombinant proteins with a high amount of mannose-6-phosphate |
| JP2020503900A (ja) | 2017-01-10 | 2020-02-06 | アミカス セラピューティックス インコーポレイテッド | ファブリー病の処置のための組換えアルファ−ガラクトシダーゼａ |
| EA202290114A1 (ru) * | 2017-03-30 | 2022-03-29 | Амикус Терапьютикс, Инк. | Способ отбора рекомбинантных белков с высоким содержанием m6p |
| EP3624831B1 (fr) * | 2017-05-15 | 2023-03-29 | Amicus Therapeutics, Inc. | Alpha-glucosidase d'acide humain recombinant |
| BR112022004000A2 (pt) | 2019-09-06 | 2022-05-31 | Amicus Therapeutics Inc | Método para captura e purificação de biológicas |
| TW202245830A (zh) * | 2021-02-11 | 2022-12-01 | 美商阿米庫斯醫療股份有限公司 | 重組人類酸性α-葡萄糖苷酶及其用途 |
| WO2023150387A1 (fr) * | 2022-02-07 | 2023-08-10 | M6P Therapeutics, Inc. | Compositions comprenant de l'alpha-glucosidase acide et leurs procédés d'utilisation |
| WO2023215865A1 (fr) | 2022-05-05 | 2023-11-09 | Amicus Therapeutics, Inc. | Méthodes de traitement de la maladie de pompe |
| WO2024119091A1 (fr) | 2022-12-02 | 2024-06-06 | Amicus Therapeutics, Inc. | Méthodes de traitement de la maladie de pompe infantile chez des patients pédiatriques |
| WO2024119070A1 (fr) | 2022-12-02 | 2024-06-06 | Amicus Therapeutics, Inc. | Méthodes de traitement de la maladie de pompe à apparition tardive chez des patients pédiatriques |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4837237A (en) | 1985-07-09 | 1989-06-06 | Fred Hutchinson Cancer Research Center | Therapy using glucosidase processing inhibitors |
| US5879680A (en) | 1987-12-23 | 1999-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | Cloned DNA for synthesizing unique glucocerebrosidase |
| US4985445A (en) | 1988-02-12 | 1991-01-15 | Meiji Seika Kaisha, Ltd. | Cancer cell metastasis inhibitors and novel compounds |
| US6451600B1 (en) | 1989-12-22 | 2002-09-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| US5236838A (en) | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| US5179023A (en) | 1989-03-24 | 1993-01-12 | Research Corporation Technologies, Inc. | Recombinant α-galactosidase a therapy for Fabry disease |
| US5011829A (en) | 1989-06-02 | 1991-04-30 | G. D. Searle & Co. | Pharmaceutical composition and method of inhibiting virus |
| US5103008A (en) | 1989-08-17 | 1992-04-07 | Monsanto Company | Compound, N-butyl-deoxynojirimycin-6-phosphate |
| US5401650A (en) | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| US5399567A (en) | 1993-05-13 | 1995-03-21 | Monsanto Company | Method of treating cholera |
| US6118045A (en) | 1995-08-02 | 2000-09-12 | Pharming B.V. | Lysosomal proteins produced in the milk of transgenic animals |
| US6458574B1 (en) | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
| US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
| US6210666B1 (en) | 1997-10-21 | 2001-04-03 | Orphan Medical, Inc. | Truncated α-galactosidase A to treat fabry disease |
| ES2216327T3 (es) | 1997-11-10 | 2004-10-16 | G.D. SEARLE & CO. | Uso de iminoazucares alquilados para tratar la resistencia a multiples a farmacos. |
| US6465488B1 (en) | 1997-12-11 | 2002-10-15 | Chancellor, Masters & Scholars Of The University Of Oxford | Inhibition of glycolipid biosynthesis |
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| ES2312222T3 (es) | 1998-12-07 | 2009-02-16 | Genzyme Corporation | Tratamiento de la enfermedad de pompe. |
| EP1165080A2 (fr) | 1999-02-12 | 2002-01-02 | G.D. SEARLE & CO. | Utilisation de composes substitues 1,5-dideoxy-1,5-imino-d-glucitol pour traiter les infections par le virus de l'hepatite |
| CA2378776A1 (fr) | 1999-07-26 | 2001-02-01 | G.D. Searle & Co. | Utilisation de derives n-alkyle de deoxynojirimycine a chaine longue et d'enzyme glucocerebro-sidase pour fabriquer un medicament permettant de traiter des maladies provoquees parle stockage de glycolipides |
| US6642038B1 (en) | 1999-09-14 | 2003-11-04 | Genzyme Glycobiology Research Institute, Inc. | GlcNAc phosphotransferase of the lysosomal targeting pathway |
| US20040204379A1 (en) | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US20020095135A1 (en) | 2000-06-19 | 2002-07-18 | David Meeker | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| EP3449934B1 (fr) | 2000-07-18 | 2020-05-20 | Duke University | Traitement d'une glycogénose de type ii |
| CN1638739A (zh) | 2000-08-18 | 2005-07-13 | 法玛西雅厄普约翰美国公司 | 治疗成瘾性障碍的化合物 |
| US7723296B2 (en) * | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
| ES2300439T3 (es) | 2001-04-30 | 2008-06-16 | Zystor Therapeutics , Inc. | Reconocimiento subcelular de proteinas terapeuticas. |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| JP2005523882A (ja) | 2001-10-16 | 2005-08-11 | アールエックスキネティックス，インコーポレイテッド | 高濃度タンパク質製剤および製造の方法 |
| AU2003224880A1 (en) | 2002-04-05 | 2003-10-27 | Genzyme Corporation | Methods of enhancing lysosomal storage disease therapy |
| HUE033381T2 (en) | 2003-01-31 | 2017-11-28 | Mount Sinai School Of Medicine Of New York Univ | Combination therapy for the treatment of protein deficiency disorders |
| FR2861991B1 (fr) | 2003-11-07 | 2008-01-18 | Centre Nat Rech Scient | Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose |
| JP2007523648A (ja) * | 2004-02-06 | 2007-08-23 | バイオマリン ファーマシューティカル インコーポレイテッド | 高リン酸化リソソーム酵素製剤及びそれらの使用 |
| DE602005020745D1 (de) | 2004-02-10 | 2010-06-02 | Zystor Therapeutics Inc | Saure alpha-glukosidase und fragmente davon |
| US20060142234A1 (en) | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
| EP3782655A1 (fr) | 2005-05-17 | 2021-02-24 | Amicus Therapeutics, Inc. | Procédé pour le traitement de la maladie de pompe au moyen de 1-désoxynojirimycine et de ses dérivés |
| CN101636200A (zh) * | 2006-11-13 | 2010-01-27 | 齐斯特治疗公司 | 用于治疗庞贝氏症的方法 |
| EP2099523A2 (fr) | 2006-11-13 | 2009-09-16 | ZyStor Therapeutics , Inc. | Méthodes de traitement de la maladie de pompe |
| US20100184803A1 (en) | 2007-03-09 | 2010-07-22 | Link Medicine Corporation | Treatment of Lysosomal Storage Diseases |
| WO2008134628A2 (fr) | 2007-04-26 | 2008-11-06 | Amicus Therapeutics, Inc. | Schémas posologiques pour le traitement de maladies de stockage lysosomal en utilisant des chaperons pharmacologiques |
| US20100317690A1 (en) | 2007-11-21 | 2010-12-16 | Summit Corporation Plc | Treatment of protein folding disorders |
| WO2009075815A1 (fr) | 2007-12-07 | 2009-06-18 | Duke University | Thérapie génique d'immunomodulation |
| PL3470077T3 (pl) | 2008-02-12 | 2021-04-06 | Amicus Therapeutics, Inc. | Sposób przewidywania odpowiedzi na leczenie chorób chaperonami farmakologicznymi |
| JP2011517556A (ja) | 2008-03-12 | 2011-06-16 | アミカス セラピューティックス インコーポレイテッド | ポンペ病のための治療選択肢を診断し評価するための検定 |
| WO2009114679A2 (fr) | 2008-03-12 | 2009-09-17 | Amicus Therapeutics, Inc | Traitement de la maladie de pompe au moyen de chaperones pharmacologiques spécifiques, et traitement de surveillance utilisant des critères de substitution |
| ES2830350T3 (es) * | 2008-05-07 | 2021-06-03 | Biomarin Pharm Inc | Péptidos de dirección lisosómica y usos de los mismos |
| WO2010015816A2 (fr) | 2008-08-06 | 2010-02-11 | Summit Corporation Plc | Traitement de troubles de stockage lysosomal et autres maladies protéostatiques |
| WO2010056746A1 (fr) | 2008-11-11 | 2010-05-20 | Amicus Therapeutics, Inc. | Régimes thérapeutiques, régimes posologiques et médicaments stables pour le traitement de la maladie de pompe |
| BR122020010601B8 (pt) | 2008-12-16 | 2021-07-27 | Genzyme Corp | conjugados de proteína-oligossacarídeo, seus usos, e composições farmacêuticas |
| US8466340B2 (en) * | 2009-02-18 | 2013-06-18 | Amicus Therapeutics, Inc. | Mouse model for pompe disease and methods of use thereof |
| AU2010233188B2 (en) | 2009-04-09 | 2015-07-16 | Amicus Therapeutics, Inc. | Methods for preventing and/or treating lysosomal storage disorders |
| ES2569514T3 (es) | 2009-06-17 | 2016-05-11 | Biomarin Pharmaceutical Inc. | Formulaciones para enzimas lisosómicas |
| JP5415170B2 (ja) | 2009-07-21 | 2014-02-12 | 富士フイルム株式会社 | 複眼撮像装置 |
| CA2775938C (fr) * | 2009-09-29 | 2021-08-10 | Oxyrane Uk Limited | Hydrolyse de la liaison du mannose-1-phospho-6-mannose au phospho-6-mannose |
| US20130196410A1 (en) | 2010-03-05 | 2013-08-01 | Alnylam Pharmaceuticals, Inc | Compositions and methods for modifying the glycosylation pattern of a polypeptide |
| WO2012042386A2 (fr) * | 2010-09-29 | 2012-04-05 | Oxyrane Uk Limited | Mannosidases capables d'éliminer la coiffe des liaisons mannose-1-phospho- 6-mannose et de démannosyler les n-glycanes phosphorylés, et méthodes facilitant l'assimilation des glycoprotéines par des cellules de mammifères |
| AU2012245280A1 (en) | 2011-04-22 | 2013-11-07 | Genzyme Corporation | Modified acid alpha glucosidase with accelerated processing |
| KR101955054B1 (ko) * | 2011-05-27 | 2019-03-07 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 리소좀 축적증의 개선된 치료를 위해 재조합 리소좀 효소상에 표적화 펩티드를 커플링시키는 방법 |
| WO2013013017A2 (fr) * | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Compositions et procédés pour modifier la glycosylation de substances thérapeutiques pour les troubles du stockage lysosomal |
| EP2735064A2 (fr) * | 2011-07-22 | 2014-05-28 | Insight Photonic Solutions, Inc. | Système et procédé de création dynamique et adaptative d'un balayage continu en longueur d'onde ayant une longueur d'onde imposée par rapport au temps à partir d'un laser |
| JP6320931B2 (ja) | 2011-12-22 | 2018-05-09 | セントジーン アイピー ゲーエムベーハー | リソソーム酵素を再構成する能力を有する化合物ならびにアンブロキソールおよび／またはアンブロキソールの誘導体の組み合わせ |
| CA2866683A1 (fr) | 2012-03-07 | 2013-09-12 | Amicus Therapeutics, Inc. | Compositions d'alpha-glucosidase a haute concentration pour le traitement de la maladie de pompe |
| PL2844279T3 (pl) * | 2012-05-03 | 2021-08-16 | Amicus Therapeutics, Inc. | Schematy dawkowania w leczeniu choroby pompego |
| WO2013182652A1 (fr) | 2012-06-06 | 2013-12-12 | Fondazione Telethon | Chaperonnes allostériques et leurs utilisations |
| TWI529396B (zh) | 2014-07-18 | 2016-04-11 | Mpi Corp | Probe card and its transfer circuit board and signal feed structure |
| EA038986B1 (ru) | 2014-09-30 | 2021-11-18 | Амикус Терапьютикс, Инк. | Высокоактивная кислая альфа-глюкозидаза с повышенным содержанием углеводов |
-
2015
- 2015-09-30 EA EA201790724A patent/EA038986B1/ru unknown
- 2015-09-30 EP EP23191307.0A patent/EP4273241A3/fr active Pending
- 2015-09-30 DK DK15845664.0T patent/DK3201320T3/da active
- 2015-09-30 US US15/515,808 patent/US10208299B2/en active Active
- 2015-09-30 IL IL289383A patent/IL289383B2/en unknown
- 2015-09-30 IL IL307587A patent/IL307587A/en unknown
- 2015-09-30 HU HUE15845664A patent/HUE064629T2/hu unknown
- 2015-09-30 JP JP2017516917A patent/JP6851964B2/ja active Active
- 2015-09-30 EP EP15845664.0A patent/EP3201320B1/fr active Active
- 2015-09-30 WO PCT/US2015/053252 patent/WO2016054231A1/fr active Application Filing
- 2015-09-30 MY MYPI2017000365A patent/MY186336A/en unknown
- 2015-09-30 AU AU2015325028A patent/AU2015325028B2/en active Active
- 2015-09-30 SG SG10202003753PA patent/SG10202003753PA/en unknown
- 2015-09-30 PL PL15845664.0T patent/PL3201320T3/pl unknown
- 2015-09-30 KR KR1020177011346A patent/KR102306577B1/ko active Application Filing
- 2015-09-30 KR KR1020227035610A patent/KR20220146662A/ko not_active Application Discontinuation
- 2015-09-30 CR CR20170107A patent/CR20170107A/es unknown
- 2015-09-30 CN CN202111483006.5A patent/CN114540327A/zh active Pending
- 2015-09-30 LT LTEPPCT/US2015/053252T patent/LT3201320T/lt unknown
- 2015-09-30 MX MX2017003989A patent/MX2017003989A/es unknown
- 2015-09-30 CA CA3228032A patent/CA3228032A1/fr active Pending
- 2015-09-30 FI FIEP15845664.0T patent/FI3201320T3/fi active
- 2015-09-30 PE PE2017000507A patent/PE20170906A1/es unknown
- 2015-09-30 SI SI201531983T patent/SI3201320T1/sl unknown
- 2015-09-30 SG SG11201702114TA patent/SG11201702114TA/en unknown
- 2015-09-30 TN TN2017000082A patent/TN2017000082A1/en unknown
- 2015-09-30 ES ES15845664T patent/ES2967620T3/es active Active
- 2015-09-30 PT PT158456640T patent/PT3201320T/pt unknown
- 2015-09-30 HR HRP20240041TT patent/HRP20240041T1/hr unknown
- 2015-09-30 CN CN201580052512.5A patent/CN107075468B/zh active Active
- 2015-09-30 KR KR1020217030450A patent/KR102455814B1/ko active IP Right Grant
- 2015-09-30 RS RS20240027A patent/RS65066B1/sr unknown
- 2015-09-30 CA CA2961762A patent/CA2961762C/fr active Active
- 2015-09-30 BR BR112017005810A patent/BR112017005810A2/pt not_active Application Discontinuation
-
2017
- 2017-03-10 PH PH12017500455A patent/PH12017500455A1/en unknown
- 2017-03-14 IL IL251152A patent/IL251152B/en active IP Right Grant
- 2017-03-20 ZA ZA2017/01945A patent/ZA201701945B/en unknown
- 2017-03-20 DO DO2017000079A patent/DOP2017000079A/es unknown
- 2017-03-23 CO CONC2017/0002776A patent/CO2017002776A2/es unknown
- 2017-03-27 CL CL2017000722A patent/CL2017000722A1/es unknown
- 2017-03-27 MX MX2021014565A patent/MX2021014565A/es unknown
- 2017-03-28 NI NI201700039A patent/NI201700039A/es unknown
- 2017-03-28 SV SV2017005416A patent/SV2017005416A/es unknown
- 2017-03-28 EC ECIEPI201719103A patent/ECSP17019103A/es unknown
-
2019
- 2019-01-18 US US16/252,505 patent/US10961522B2/en active Active
- 2019-03-19 ZA ZA2019/01690A patent/ZA201901690B/en unknown
-
2020
- 2020-09-23 IL IL277529A patent/IL277529B/en unknown
- 2020-09-25 JP JP2020161470A patent/JP7225176B2/ja active Active
-
2021
- 2021-02-23 US US17/249,175 patent/US11753632B2/en active Active
-
2022
- 2022-02-04 US US17/665,179 patent/US11591583B2/en active Active
- 2022-05-24 AU AU2022203498A patent/AU2022203498A1/en active Pending
-
2023
- 2023-02-08 JP JP2023017964A patent/JP2023078118A/ja active Pending
- 2023-02-17 US US18/111,321 patent/US20230203465A1/en active Pending
-
2024
- 2024-03-28 FR FR24C1012C patent/FR24C1012I1/fr active Active
- 2024-04-02 HU HUS2400007C patent/HUS2400007I1/hu unknown
- 2024-04-03 FI FIC20240010C patent/FIC20240010I1/fi unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR24C1012I1 (fr) | Alpha-glucosidase acide très puissante ayant des hydrates de carbone améliorés | |
| MA41217A (fr) | Polythérapies ayant des souches de listeria recombinées | |
| SI3119918T1 (sl) | Nizkostroškovno jeklo z izjemno visoko prevodnostjo | |
| PL3094593T3 (pl) | Mikroinstalacja węglowa | |
| KR20180084862A (ko) | 탄소 복합체 | |
| GB201405834D0 (en) | Oncolytic virus | |
| DK3200213T3 (da) | Jævnstrømsafbryder | |
| FR3016371B1 (fr) | Levures modifiees pour utiliser le dioxyde de carbone | |
| EP3194335A4 (fr) | Composites à base de carbone | |
| SG11201505201TA (en) | Protein purification in the presence of nonionic organic polymers at elevated conductivity | |
| GB201403063D0 (en) | Quantum technology | |
| GB2540285B (en) | Carbon nanotube transistor having extended contacts | |
| EP3190991A4 (fr) | Dispositif de nettoyage de langue par ultrasons haute intensité | |
| GB201421830D0 (en) | Carbon Nanotube | |
| DK3099515T3 (da) | Massivt dæk med trækkabel | |
| CL2015001184S1 (es) | Conector | |
| PL3052650T3 (pl) | Wykrywanie mykobakterii za pomocą bakteriofagów | |
| ES1135607Y (es) | Laringoscopio con pala fungible | |
| ES1130981Y (es) | Lampara electrica | |
| FR3022212B1 (fr) | Tricycle utilitaire ameliore | |
| TH1601003812A (th) | วิธีและออร์แกนิซึมที่มีประสิทธิภาพคาร์บอนฟลักซ์เพิ่มขึ้น | |
| TH1601002158A (th) | การดักจับคาร์บอนในการหมักที่ถูกทำให้ดีขึ้น | |
| GB201419474D0 (en) | Carbon nanotube | |
| ES2654061T8 (es) | Conector | |
| ES1136656Y (es) | Ladrillo de vidrio de baja emision |